R&D channel feed – Endpoints News

R&D channel feed

Merck and Eisai's Keytruda/Lenvima combo fails PhIII trials for melanoma, colorectal cancer

3 years ago

Immunic touts positive data in maintenance phase of failed PhII trial, pulls back on another asset

3 years ago

Private startup claims a PhIIa win in subset of ALS patients, but questions remain

3 years ago

Takeda ending discovery, preclinical work in AAV gene therapy, rare hematology

3 years ago

AI tools don't equal guaranteed drug success as BenevolentAI flops dermatitis test

3 years ago

Pfizer RSV data set up $10B showdown with GSK and Moderna for the next big vaccine market

3 years ago

Amgen's denosumab shows promise in small, NIH-funded rare bone disease study

3 years ago

Incyte links arms with tiny Biotheryx for protein degrader deal, targeting cancer

3 years ago

Ginkgo snaps up gene therapy vector assets from StrideBio

3 years ago

AstraZeneca's Lynparza-Imfinzi combo clears PhIII trial in ovarian cancer

3 years ago

Estée Lauder's family injects $200M into Alzheimer’s Drug Discovery Foundation

3 years ago

Akebia touts new data on anemia drug a year after rejection

3 years ago

As market stays cold, biotechs continue to cut programs, trials and staff

3 years ago

OncoSec reports flop for IL-12/Keytruda combo in what may be final blow

3 years ago

Two patient deaths lead to FDA partial hold for Gossamer trial of lymphoma drug

3 years ago

Biotech launched during Covid — for Covid — looks for strategic alternatives after antiviral fails PhII trial

3 years ago

AstraZeneca inks deal with Japanese biotech JCR in CNS indication

3 years ago

FTC orders Illumina to divest Grail, adding pressure amid activist fight with Icahn

3 years ago

Takeda pays $5M upfront to license antibodies for celiac disease drug development

3 years ago

Cytokinetics’ ALS drug fails PhIII, leaving the biotech with a single late-stage prospect

3 years ago

CHMP gives thumbs-up for Wegovy use in adolescents, along with nine new drug recommendations

3 years ago

Austin biotech Molecular Templates lays off more than 100 staffers as pipeline narrows

3 years ago

Aptinyx evaluates future of the company following two failed trials, 60% layoffs

3 years ago

Nanoscope’s eye disease gene therapy shows mixed results in PhII

3 years ago

First page Previous page 92 93 949596 97 98 Next page Last page